Memantine Sandoz

Memantine Hydrochloride, the active ingredient in Memantine Sandoz, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of cognitive decline associated with Alzheimer's disease in adult patients.

GNH USA supplies Memantine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution. Clients benefit from reliable logistics, competitive pricing, and responsive technical support for product handling.

Memantine Sandoz is an NMDA receptor antagonist used in the management of Alzheimer’s disease.

Alzheimer's disease (mild): may help maintain daily functioning and memory performance. Mild to moderate Alzheimer's disease: may slow cognitive decline and support daily activities. Behavioral symptoms of Alzheimer’s disease: may reduce agitation and improve overall patient cooperation. Moderate Alzheimer's disease: may improve cognition and functional abilities in patients with established disease.

Common Side Effects: - Dizziness: transient sensation of light‑headedness or imbalance. - Headache: mild to moderate intensity, often resolving without intervention. - Constipation: reduced bowel movements, manageable with diet or laxatives. - Confusion: occasional episodes of mental clouding, especially at treatment initiation. - Hypertension: modest increase in blood pressure in some patients.

Serious or Rare Side Effects: - Seizures: rare occurrence, requiring immediate medical attention. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Cardiac arrhythmias: irregular heart rhythms observed in isolated cases.

Memantine Sandoz should be used with caution in the following situations: - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic impairment: monitor liver function tests regularly. - Concomitant NMDA antagonists: avoid combining with other agents that block NMDA receptors. - History of seizures: assess risk‑benefit ratio before initiating therapy. - Pregnancy and breastfeeding: safety not established; use only if potential benefit justifies potential risk. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine Sandoz may interact with several medicines. Review the following categories:

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism can increase neurotoxicity. - Other NMDA antagonists (e.g., dextromethorphan): may enhance central nervous system depression. - Drugs that lower seizure threshold (e.g., bupropion): may increase risk of seizures.

Moderate Interactions (Monitor Closely): - Strong CYP450 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma concentrations of memantine. - Anticholinergic agents: may mask cognitive benefits of memantine and require clinical monitoring.